PubMed

Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.

Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y, Kamiya H, Koh N, Hotta N.

Diabetes Care. 2001 Jun;24(6):1093-8.PMID: 11375376 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.

Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y.

Diabetes Care. 2006 Jul;29(7):1538-44.PMID: 16801576 [PubMed - indexed for MEDLINE]Related articlesFree article

Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.

Misawa S, Kuwabara S, Kanai K, Tamura N, Nakata M, Sawai S, Yagui K, Hattori T.

Neurology. 2006 May 23;66(10):1545-9.PMID: 16717216 [PubMed - indexed for MEDLINE]Related articles

[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]

Shimada H, Miki T, Kyogoku I, Kawagishi T, Inaba M, Okuno Y, Nishizawa Y, Morii H.

No To Shinkei. 1998 Sep;50(9):817-20. Japanese. PMID: 9789304 [PubMed - indexed for MEDLINE]Related articles

Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.

Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.

J Diabetes Complications. 1999 May-Jun;13(3):141-50.PMID: 10509874 [PubMed - indexed for MEDLINE]Related articles

Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.

Okamoto H, Nomura M, Nakaya Y, Uehara K, Saito K, Kimura M, Chikamori K, Ito S.

Intern Med. 2003 Aug;42(8):655-64.PMID: 12924487 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.

Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y.

J Diabetes Complications. 1996 May-Jun;10(3):168-72.PMID: 8807467 [PubMed - indexed for MEDLINE]Related articles

A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT).

Matsuoka K, Sakamoto N, Akanuma Y, Hotta N, Shichiri M, Toyota T, Oka Y, Kawamori R, Shigeta Y; ADCT Study Group.

Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S263-8. Epub 2007 Jun 27.PMID: 17599629 [PubMed - indexed for MEDLINE]Related articles

Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.

Hotta N, Kawamori R, Atsumi Y, Baba M, Kishikawa H, Nakamura J, Oikawa S, Yamada N, Yasuda H, Shigeta Y; ADCT Study Group.

Diabet Med. 2008 Jul;25(7):818-25.PMID: 18644069 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.

Ikeda T, Iwata K, Tanaka Y.

Diabetes Res Clin Pract. 1999 Mar;43(3):193-8.PMID: 10369429 [PubMed - indexed for MEDLINE]Related articles

Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.

Uchida K, Kigoshi T, Nakano S, Ishii T, Kitazawa M, Morimoto S.

Clin Ther. 1995 May-Jun;17(3):460-6.PMID: 7585850 [PubMed - indexed for MEDLINE]Related articles

Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.

Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N.

Diabetes Care. 2000 Oct;23(10):1539-44.PMID: 11023149 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.

Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R.

Biomed Pharmacother. 1995;49(6):269-77.PMID: 7579007 [PubMed - indexed for MEDLINE]Related articles

I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.

Utsunomiya K, Narabayashi I, Nakatani Y, Tamura K, Onishi S.

Clin Nucl Med. 1999 Jun;24(6):418-20.PMID: 10361937 [PubMed - indexed for MEDLINE]Related articles

One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.

Ziegler D, Mayer P, Rathmann W, Gries FA.

Diabetes Res Clin Pract. 1991 Oct;14(1):63-73.PMID: 1748064 [PubMed - indexed for MEDLINE]Related articles

Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.

Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N; SNK-860 Diabetic Neuropathy Study Group.

Diabetes Care. 2001 Oct;24(10):1776-82. Erratum in: Diabetes Care 2002 Feb;25(2):413-4. PMID: 11574441 [PubMed - indexed for MEDLINE]Related articlesFree article

Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.

Ando H, Takamura T, Nagai Y, Kaneko S; Kanazawa University Multicenter Diabetes Study Group.

J Diabetes Complications. 2006 Nov-Dec;20(6):367-70.PMID: 17070440 [PubMed - indexed for MEDLINE]Related articles

Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.

Ramirez MA, Borja NL.

Pharmacotherapy. 2008 May;28(5):646-55. Review.PMID: 18447661 [PubMed - indexed for MEDLINE]Related articles

A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.

Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kito S, Matsuoka K, Takahashi A, Kikkawa R, Sakuma A.

Diabet Med. 1993;10 Suppl 2:39S-43S. No abstract available. PMID: 8334840 [PubMed - indexed for MEDLINE]Related articles

Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.

Kurata C, Okayama K, Wakabayashi Y, Shouda S, Mikami T, Tawarahara K, Sugiyama T.

J Nucl Med. 1997 Nov;38(11):1677-80.PMID: 9374332 [PubMed - indexed for MEDLINE]Related articlesFree article